Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In a pandemic, the development of an effective influenza vaccine is the most important subject from the view of public health. This study was performed to evaluate the immunogenicity and safety of inactivated, monovalent H1N1 2009 vaccine (Green Cross Corporation, Yongin, Korea) among healthy adults aged 19-64 years (Group 1) and the elderly aged ≥65 years (Group 2) in a two-dose regimen, 21 days apart. At baseline, 28 of 454 participants (6.1%) had hemagglutination-inhibition titers of ≥1:40 with no significant difference between age groups (p=0.27). There was an apparent dose-dependent antibody response; participants receiving the dose of 30μg hemagglutinin (HA) showed higher geometric mean titers (GMTs) than the 15μg HA group in both age groups. Despite the rates of seroprotection and seroconversion were significantly higher with 30μg HA formulation than 15μg HA formula in Group 2, there was no definite difference in Group 1 irrespective of vaccine formula. Significant GMT elevation after the second dose was not noted in either age group, regardless vaccine formulations. No deaths, vaccine-related serious adverse events, or immediate unsolicited adverse reactions occurred during the study periods.

Original languageEnglish
Pages (from-to)523-527
Number of pages5
JournalVaccine
Volume29
Issue number3
DOIs
Publication statusPublished - 2011 Jan 10

Fingerprint

Inactivated Vaccines
Hemagglutinins
Korea
influenza
Human Influenza
Korean Peninsula
hemagglutinins
Vaccines
immune response
vaccines
Safety
Age Groups
dosage
Influenza Vaccines
Hemagglutination
Pandemics
corporations
Antibody Formation
seroconversion
pandemic

Keywords

  • 2009 H1N1
  • Immunogenicity
  • Influenza
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. / Cheong, Hee-Jin; Song, Joon-Young; Heo, Jung Yeon; Noh, Ji Yun; Choi, Wonseok; Park, Dae Won; Wie, Seong Heon; Kim, Woo Joo.

In: Vaccine, Vol. 29, No. 3, 10.01.2011, p. 523-527.

Research output: Contribution to journalArticle

@article{a76b543b55af4727a9935cfdb4e477e0,
title = "Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea",
abstract = "In a pandemic, the development of an effective influenza vaccine is the most important subject from the view of public health. This study was performed to evaluate the immunogenicity and safety of inactivated, monovalent H1N1 2009 vaccine (Green Cross Corporation, Yongin, Korea) among healthy adults aged 19-64 years (Group 1) and the elderly aged ≥65 years (Group 2) in a two-dose regimen, 21 days apart. At baseline, 28 of 454 participants (6.1{\%}) had hemagglutination-inhibition titers of ≥1:40 with no significant difference between age groups (p=0.27). There was an apparent dose-dependent antibody response; participants receiving the dose of 30μg hemagglutinin (HA) showed higher geometric mean titers (GMTs) than the 15μg HA group in both age groups. Despite the rates of seroprotection and seroconversion were significantly higher with 30μg HA formulation than 15μg HA formula in Group 2, there was no definite difference in Group 1 irrespective of vaccine formula. Significant GMT elevation after the second dose was not noted in either age group, regardless vaccine formulations. No deaths, vaccine-related serious adverse events, or immediate unsolicited adverse reactions occurred during the study periods.",
keywords = "2009 H1N1, Immunogenicity, Influenza, Vaccination",
author = "Hee-Jin Cheong and Joon-Young Song and Heo, {Jung Yeon} and Noh, {Ji Yun} and Wonseok Choi and Park, {Dae Won} and Wie, {Seong Heon} and Kim, {Woo Joo}",
year = "2011",
month = "1",
day = "10",
doi = "10.1016/j.vaccine.2010.10.060",
language = "English",
volume = "29",
pages = "523--527",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea

AU - Cheong, Hee-Jin

AU - Song, Joon-Young

AU - Heo, Jung Yeon

AU - Noh, Ji Yun

AU - Choi, Wonseok

AU - Park, Dae Won

AU - Wie, Seong Heon

AU - Kim, Woo Joo

PY - 2011/1/10

Y1 - 2011/1/10

N2 - In a pandemic, the development of an effective influenza vaccine is the most important subject from the view of public health. This study was performed to evaluate the immunogenicity and safety of inactivated, monovalent H1N1 2009 vaccine (Green Cross Corporation, Yongin, Korea) among healthy adults aged 19-64 years (Group 1) and the elderly aged ≥65 years (Group 2) in a two-dose regimen, 21 days apart. At baseline, 28 of 454 participants (6.1%) had hemagglutination-inhibition titers of ≥1:40 with no significant difference between age groups (p=0.27). There was an apparent dose-dependent antibody response; participants receiving the dose of 30μg hemagglutinin (HA) showed higher geometric mean titers (GMTs) than the 15μg HA group in both age groups. Despite the rates of seroprotection and seroconversion were significantly higher with 30μg HA formulation than 15μg HA formula in Group 2, there was no definite difference in Group 1 irrespective of vaccine formula. Significant GMT elevation after the second dose was not noted in either age group, regardless vaccine formulations. No deaths, vaccine-related serious adverse events, or immediate unsolicited adverse reactions occurred during the study periods.

AB - In a pandemic, the development of an effective influenza vaccine is the most important subject from the view of public health. This study was performed to evaluate the immunogenicity and safety of inactivated, monovalent H1N1 2009 vaccine (Green Cross Corporation, Yongin, Korea) among healthy adults aged 19-64 years (Group 1) and the elderly aged ≥65 years (Group 2) in a two-dose regimen, 21 days apart. At baseline, 28 of 454 participants (6.1%) had hemagglutination-inhibition titers of ≥1:40 with no significant difference between age groups (p=0.27). There was an apparent dose-dependent antibody response; participants receiving the dose of 30μg hemagglutinin (HA) showed higher geometric mean titers (GMTs) than the 15μg HA group in both age groups. Despite the rates of seroprotection and seroconversion were significantly higher with 30μg HA formulation than 15μg HA formula in Group 2, there was no definite difference in Group 1 irrespective of vaccine formula. Significant GMT elevation after the second dose was not noted in either age group, regardless vaccine formulations. No deaths, vaccine-related serious adverse events, or immediate unsolicited adverse reactions occurred during the study periods.

KW - 2009 H1N1

KW - Immunogenicity

KW - Influenza

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=78650521372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650521372&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.10.060

DO - 10.1016/j.vaccine.2010.10.060

M3 - Article

C2 - 21055502

AN - SCOPUS:78650521372

VL - 29

SP - 523

EP - 527

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 3

ER -